1 Guidance

1.1 Current evidence on the safety and efficacy of therapeutic percutaneous image-guided aspiration of spinal cysts is very limited but is adequate to support the use of the procedure in the context of this rare condition, provided that normal arrangements are in place for clinical governance and audit.

1.2 During the consent process, clinicians should ensure that patients understand that there is uncertainty about the procedure's benefits and that subsequent interventions may be necessary. They should provide patients with clear written information. In addition, use of the Institute's information for patients ('Understanding NICE guidance') is recommended.
2 The procedure

2.1 Indications

2.1.1 There are several types of spinal cyst, all of which are rare. Tarlov or perineural cysts affect nerve roots, most commonly in the sacral region of the spine. The majority are asymptomatic, but they may occasionally cause symptoms such as radicular pain or urinary dysfunction. Arachnoid cysts develop as a result of defects of the dura, usually in the thoracic region of the spine. They can cause radicular pain or loss of sensory or motor function. Spinal echinococcal cysts are a rare feature of hydatid disease, and may also cause radicular pain or loss of neurological function.

2.1.2 Painful spinal cysts are often managed conservatively with analgesics. Open surgery to drain or remove cysts may be indicated if pain is refractory to medical therapy, or if there is a threat of permanent neurological impairment.

2.2 Outline of the procedure

2.2.1 A small-gauge needle is inserted into the cyst under computed tomography (CT) or magnetic resonance imaging (MRI) guidance. Cyst contents are aspirated, and the decrease in cyst volume is documented by imaging. Where cysts are present at more than one spinal level, several aspiration procedures may be needed.

2.3 Efficacy

2.3.1 The evidence available is from one case series and three case reports. In a case series of three patients with sacral perineural cysts, two experienced pain relief for up to 3 weeks and one for several weeks (number not stated). Case reports of two patients, one with an arachnoid cyst and one with spinal hydatid cysts, reported that image-guided aspiration rendered each patient asymptomatic during follow-up of 1 year. A case report of a patient with a Tarlov cyst reported that aspiration
produced immediate pain relief; however, pain recurred after 5 days and the patient underwent open decompression.

2.3.2 Follow-up imaging of cysts was undertaken in the case series and one of the case reports described above. The patient with hydatid cysts demonstrated collapsed cysts and spinal cord decompression on MRI at 4-month follow-up. Conversely, the cysts eventually refilled in the three patients with sacral perineural cysts and all subsequently received operative treatment. For more details, refer to the 'Sources of evidence' section.

2.3.3 The Specialist Advisers did not raise concerns about the efficacy of this rare procedure.

2.4 Safety

2.4.1 Only one case report, of a patient whose spinal hydatid cysts were aspirated under CT guidance, reported safety outcomes. The patient tolerated the procedure well, with no allergy or anaphylaxis. For more details, refer to the 'Sources of evidence' section.

2.4.2 The Specialist Advisers listed potential adverse events as bleeding, infection, and nerve or spinal cord damage, including paraplegia.

Andrew Dillon
Chief Executive
June 2007

3 Further information

Sources of evidence

The evidence considered by the Interventional Procedures Advisory Committee is described in the following document.

‘Interventional procedure overview of therapeutic percutaneous image-guided aspiration
of spinal cysts', December 2006.

Information for patients

NICE has produced information on this procedure for patients and carers ('Understanding NICE guidance'). It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind.

4 About this guidance

NICE interventional procedure guidance makes recommendations on the safety and efficacy of the procedure. It does not cover whether or not the NHS should fund a procedure. Funding decisions are taken by local NHS bodies after considering the clinical effectiveness of the procedure and whether it represents value for money for the NHS. It is for healthcare professionals and people using the NHS in England, Wales, Scotland and Northern Ireland, and is endorsed by Healthcare Improvement Scotland for implementation by NHSScotland.

This guidance was developed using the NICE interventional procedure guidance process.

We have produced a summary of this guidance for patients and carers. Information about the evidence it is based on is also available.

Changes since publication

14 January 2012: minor maintenance.

Your responsibility

This guidance represents the views of NICE and was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or
providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

Copyright

© National Institute for Health and Clinical Excellence 2007. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

Contact NICE

National Institute for Health and Clinical Excellence
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT

www.nice.org.uk
nice@nice.org.uk
0845 033 7780

Endorsing organisation

This guidance has been endorsed by Healthcare Improvement Scotland.